• 333 patients randomized and dosed in the ACTION3 Phase 3 clinical study
• Recruitment of paediatric patients ongoing as an independent cohort
• Full 2-year study expected to complete in March 2028

Dimerix Limited, a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, has announced that the ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) has now successfully completed dosing the last adult patient recruited into the study, bringing the final enrolment to 333 adult patients. The target recruitment and dosing of 286 adult patients was completed in December 2025, but as per standard practice, patients that were in the screening process at the time were allowed to progress to randomisation and dosing if still eligible, resulting in this over-recruitment. The ACTION3 Phase 3 study is a pivotal, multi-centre, randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in FSGS patients receiving a stable dose of an angiotensin II receptor blocker (ARB). The study has now successfully passed seven scheduled Independent Data Monitoring Committee (IDMC) reviews with no changes to the protocol required or safety concerns identified. Recruitment of paediatric patients remains ongoing as an independent cohort in the trial as agreed with regulators. The full 2-year treatment period of the study is expected to complete in March 2028.